The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)–positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors.
D. Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
J. K. Lee
No relevant relationships to disclose
H. S. Park
No relevant relationships to disclose
K. Kulig
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
T. M. Kim
No relevant relationships to disclose
S. Lee
No relevant relationships to disclose
Y. Jeon
No relevant relationships to disclose
D. H. Chung
Consultant or Advisory Role - Pfizer
D. S. Heo
No relevant relationships to disclose
W. H. Kim
No relevant relationships to disclose
Y. Bang
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer